Compare Bank of America Corp (BAC) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Quest Diagnostics Inc — how do they compare? Bank of America Corp trades at $61.07 (market cap $425.43B), while Quest Diagnostics Inc trades at $205.45 (market cap $22.80B). The key difference: Bank of America Corp is far larger — about 18.7× Quest Diagnostics Inc's market cap, and Bank of America Corp pays the higher dividend (1.85%). Which is the better fit depends on your goals.
| BAC | DGX | |
|---|---|---|
Market Cap | $425.43B | $22.80B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $216.02 |
52-Week Low | $44.92 | $166.42 |
Dividend Yield | 1.85% | 1.67% |
Enterprise Value | — | $28.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $59.50, down 0.28% today, with a bullish technical outlook and strong fundamental support. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.21 exceeding the $1.13 estimate. Revenue growth accelerated to $113.1 billion in 2025, and the P/E ratio of 14 remains attractive. Recent news highlights strategic partnerships and hiring initiatives, reinforcing long-term growth prospects.
BAC presents a favorable investment case with solid profitability, a 64.8% analyst buy rating, and a consensus price target of $63.79 offering 7.2% upside. Risks include sensitivity to interest rates and macroeconomic volatility, but the bank's deposit franchise and capital flexibility provide resilience. The stock is well-positioned for steady appreciation amid supportive technicals and fundamental strength.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
